leisure time -WSS

leisure time

author：comprehensive 2025-10-02 19:20:21 - browse：676

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： As H5N1 spreads in cows, experts warn against drinking raw milk

WSS

ALS treatment from Biogen, Ionis fails in study

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Abbott's new stent may help patients with peripheral artery disease

ACA's risk program benefits Blue Cross Blue Shield insurers

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Home health providers sue Medicare over payment cuts

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Activists slam private health insurers over coverage restrictions

Judge agrees to delay next hearing in Trump classified documents case

Apple is now the first public company to be valued at $3 trillion

Supreme Court to hear if Covid misinformation is protected speech

Novavax promises a turnaround & Lilly roils the obesity market

As H5N1 spreads in cows, experts warn against drinking raw milk

Wildfire smoke exposes gaps in outdoor worker protections

Create a giant ice tray with this foil pan hack to keep food cold this summer

entertainment

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

What a koala virus tells us about the human genome

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Medicare wants to send $9 billion to 340B hospitals

hotspot

Wikipedia

focus

Wikipedia